Amarin Corporation plc
Rank #349DeclineAMRN · Nasdaq · Healthcare
Amarin Corporation plc (AMRN) — Rank #349 by gross profitability (GP/assets 0.19) · ROE -8.7% · Piotroski F-Score N/A.
As-of 2026-09-28 · CIK 0000897448 · all metrics point-in-time as of the filing date.
About
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
Show moreShow less
It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.
Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- State
- X0
- Filer Category
- Accelerated filer
- Fiscal Year End
- December 31
- Website
- amarincorp.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-03-02 | 2024-12-31filed 2025-03-12 | 2023-12-31filed 2024-02-29 | 2022-12-31filed 2023-03-01 |
|---|---|---|---|---|
| Assets | ||||
| Cash & equivalents | 134.7 | 121.0 | 199.3 | 217.7 |
| Short-term investments | 167.9 | 173.2 | 121.4 | 91.7 |
| Accounts receivable | 126.8 | 122.3 | 133.6 | 131.0 |
| Inventory | 195.9 | 166.0 | 258.6 | 228.7 |
| Total current assets | 649.9 | 595.4 | 725.0 | 689.1 |
| Property, plant & equipment, net | 0.0 | 0.0 | 0.1 | 0.9 |
| Total assets | 670.8 | 685.3 | 831.7 | 886.2 |
| Liabilities | ||||
| Accounts payable | 45.4 | 40.4 | 52.8 | 64.6 |
| Deferred revenue | 0.0 | 0.0 | 2.3 | 2.2 |
| Total current liabilities | 194.5 | 179.9 | 259.3 | 259.5 |
| Total debt | — | — | — | — |
| Total liabilities | 211.5 | 199.2 | 279.6 | 290.8 |
| Equity | ||||
| Retained earnings | (1,707.3) | (1,668.5) | (1,586.4) | (1,527.3) |
| Total shareholders' equity | 459.3 | 486.2 | 552.1 | 595.3 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?